<?xml version="1.0" encoding="UTF-8"?>
<ref id="dkx118-B80">
 <label>80</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Sax</surname>
    <given-names>PE</given-names>
   </name>,
   <name name-style="western">
    <surname>DeJesus</surname>
    <given-names>E</given-names>
   </name>,
   <name name-style="western">
    <surname>Crofoot</surname>
    <given-names>G</given-names>
   </name>
  </person-group>
  <etal/>
  <article-title>Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial</article-title>.
  <source>Lancet HIV</source>
  <year>2017</year>; 
  <volume>4</volume>:
  <fpage>e154</fpage>â€“
  <lpage>e160</lpage>.
  <pub-id pub-id-type="pmid">28219610</pub-id>
 </mixed-citation>
</ref>
